CORONA Remedies Files Annual Secretarial Compliance Report for FY26
CORONA Remedies Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms compliance with SEBI regulations, including LODR, insider trading, and corporate governance norms. The company maintained its website, had no director disqualifications, and followed proper board processes.
This is a routine annual compliance report and does not involve any material financial changes, strategic shifts, or significant corporate actions that would impact the company's stock price or operations.
The announcement is a routine compliance filing and does not contain any specific financial or business performance updates that would indicate a positive or negative sentiment.
CORONA Remedies Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by M/s. Dhara Patel, Company Secretaries, confirms the company's compliance with applicable statutory provisions and good corporate practices during the review period.
The review covered compliance with the SEBI Act, SCRA, and various SEBI regulations, including Listing Obligations and Disclosure Requirements (LODR), Issue of Capital and Disclosure Requirements, Substantial Acquisition of Shares and Takeovers, Prohibition of Insider Trading, and Depositories and Participants Regulations. The report indicates that CORONA Remedies Limited has adopted and timely updated its policies, maintained a functional website with timely dissemination of information, and ensured its directors are not disqualified. The company also demonstrated compliance in areas such as subsidiary identification (where applicable), document preservation, performance evaluation of the board and committees, related party transactions, and timely disclosure of events and information.
Furthermore, the company is in compliance with the Prohibition of Insider Trading Regulations, including the maintenance of a Structured Digital Database. No actions have been taken against the listed entity, its promoters, directors, or subsidiaries by SEBI or Stock Exchanges during the review period. The report also notes that no statutory auditors resigned during the financial year. The company confirmed that it has taken prior approval from the Audit Committee for all related party transactions. The report was prepared on a test-check basis, relying on records and explanations provided by the management.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.